Company Overview and News

to your dashboard

Headline News

Celyad: Why Did It Go Down Recently?

2017-11-15 seekingalpha
In this piece, Dr Maiya follows up on his coverage on Celyad (CYAD), and discusses some data released from the THINK trial.

Edison Issues ADR Update on Celyad (CYAD)

2017-10-30 accesswire
LONDON, UK / ACCESSWIRE / October 30, 2017 / Celyad SA (NASDAQ: CYAD) has reported a complete morphological leukemia-free status (MFLS) response in acute myeloid leukemia (AML) in the NKR CAR T-cell THINK study. Spontaneous remission in refractory/relapsed AML is extremely rare, so this is a significant result. Importantly, the response was achieved with no toxic preconditioning. CYAD-01 has shown limited toxicities to date.

Will Biotech Continue To Boom?

2017-10-12 seekingalpha
Avisol Capital Partners joins the Roundtable to discuss their approach to biotech valuations and the warning signs they look for in the stocks they research. (64-1)

3 Things In Biotech You Should Learn Today: October 4, 2017

2017-10-04 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Celyad: Some Questions For Management

2017-07-07 seekingalpha
I recently covered Celyad (CYAD), a small Belgian company developing CAR-T therapy for solid tumors, and I have a few follow up questions. Some of these needs to be answered by management, but some I could probably answer.

Gilead And CAR-T Of Solid Tumors: The Next Revolution In Cancer Therapeutics

2017-06-28 seekingalpha
However, the onco space is one that can offer a good replacement option for its HCV franchise.

Buy Celyad And Get In On The CAR-T Space In Solid Tumors: Medicine's Next Frontier

2017-06-27 seekingalpha
In the entire field of oncology, perhaps the most disruptive ongoing revolution is the application of Chimeric Antigen Receptor - T Cells or (CAR-T) to cancer immunotherapy. In this therapy, engineered T-cells that express a specific tumor antigen binding domain called Chimeric Antigen Receptor is infused into the patient. As the construct binds to its target domain, the T-cell is activated and attacks the cancer cell with great specificity.

TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come

2017-06-27 seekingalpha
The biotech has signed a $400+ million deal with big pharma Takeda for its lead asset, Cx601, which should be approved in Europe before YE2017

Myelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch

2017-06-21 prnewswire adds "Myelodysplastic Syndrome Pipeline Review H1 2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.

3 Biotech Stocks That More than Doubled Year to Date

2017-06-19 zacks
We are almost half way through 2017 and the biotech sector, which had a rough and challenging 2016, has been showing signs of recovery despite some ups and downs. Year-to-date (YTD), the NASDAQ Biotechnology Index is up 10.4% providing a glimmer of hope to biotech investors who saw the Index sliding 19.1% in 2016.      While the drug pricing issue remains a headline risk this year as well, confidence in the sector has been boosted by strong results, R&D success and innovation, FDA approvals, ramp up in new product sales and continued strong performance from legacy products.

Novartis: Follow The (Belgian) Yellow Brick Road

2017-05-18 seekingalpha
Novartis will release the interim data from the JULIET trial, during the International Conference on Malignant Lymphoma.

Pipeline of Congestive Heart Failure Market Review Research for H1 2017 - Reports and Reports

2017-03-22 prnewswire adds "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

U.S. Money and Local Talent the Growth Plan for European Biotech - Bloomberg

2017-01-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Bayer And Versant's Big Bet On Stem Cells

2016-12-14 seekingalpha
Repeated failure has not dissuaded the sector from chasing the hypothesis that cardiac tissue can be regenerated with stem cell therapy. The latest players are Bayer (OTCPK:BAYZF, OTCPK:BAYRY) and Versant Ventures, which invested $225m in Bluerock Therapeutics, a business that will focus on cardiovascular disease as its lead programme.